Office of Research & Development |
![]() ![]() |
Project Number: | IK2BX004341-01A1 |
Title: | Understanding how DOPA decarboxylase modulates tau in disease |
Principal Investigator: | Rebecca Kow |
Location: | Seattle, WA |
Congressional District Code: | 9 |
Research Service: | Biomedical Laboratory R&D |
Project Period: | January 2019 - December 2023 |
FY 2021 Funding Amount: | $194,631 |
Total Award Amount (all years): |
$971,862 |
Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Background: Neurodegenerative diseases with tau pathology (tauopathies) include Alzheimer's disease and chronic traumatic encephalopathy. Two major risk factors for developing tauopathies are aging and repetitive mild traumatic brain injury. The prevalence of tauopathies is expected to rise, especially among Veterans. However, there are no clinically-approved treatments for tauopathies. DOPA decarboxylase, the second enzyme in dopamine and serotonin synthesis, was recently identified as a novel... |